Welcome and introduction (ID 4748)
MET pathway and overcoming MET resistance in NSCLC (ID 4749)
Designing a pragmatic strategy for targeting c-MET in NSCLC (ID 4750)
Applying a new mechanism of action and emerging predictive biomarker to inform precision treatment decisions in patients with advanced NSCLC (ID 4751)
Panel discussion and Q&A (ID 4752)
Summary and conclusions (ID 5540)
